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Abstract: Exposure to high levels of estrogen is considered an important risk factor for 
susceptibility to breast cancer. Common polymorphisms in genes that affect estrogen levels 
may be associated with breast cancer risk, but no comprehensive study has been performed 
among Han Chinese women. In the present study, 32 single-nucleotide polymorphisms 
(SNPs) in estrogen-related genes were genotyped using the MassARRAY IPLEX platform 
in 1076 Han Chinese women. Genotypic and allelic frequencies were compared between 
case and control groups. Unconditional logistic regression was used to assess the effects of 
SNPs on breast cancer risk. Associations were also evaluated for breast cancer subtypes 
stratified by estrogen receptor (ER) and progesterone receptor (PR) status. Case-control 
analysis showed a significant relation between heterozygous genotypes of rs700519 and 
rs2069522 and breast cancer risk (OR = 0.723, 95% CI = 0.541–0.965, p = 0.028 and  
OR = 1.500, 95% CI = 1.078–2.087, p = 0.016, respectively). Subgroup comparisons revealed 
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that rs2446405 and rs17268974 were related to ER status, and rs130021 was associated 
with PR status. Our findings suggest that rs700519 and rs2069522 are associated with 
susceptibility to breast cancer among the Han Chinese population and have a cumulative 
effect with three other identified SNPs. Further genetic and functional studies are needed to 
identify additional SNPs, and to elucidate the underlying molecular mechanisms. 
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1. Introduction 
Breast cancer is one of the most common malignancies in women, and it causes serious health 
issues in women worldwide [1]. Although the incidence rate of breast cancer is currently low in China 
compared to Western countries, it is increasing rapidly. If current trends continue, the incidence rate  
in China will rise to approximately 85 per 100,000 woman-years by 2021 [2]. It is widely recognized 
that breast cancer development is the consequence of complex interactions between the genome, 
lifestyle, and environment. Many factors including family history, high mammographic density, 
postmenopausal hormone use, early age of menarche, late first pregnancy, breastfeeding for short 
periods, lower parity, and a longer interval between births have been confirmed to be associated with 
breast cancer susceptibility [3]. In addition, inheritance and hormones have also been suggested to be 
important risk factors [4,5]. 
The normal growth and function of breast epithelial cells are under hormonal control. Estrogen acts 
as a key driver for breast cancer because it can increase the frequency of mitotic activity, thereby 
stimulating cell divisions and increasing the potential of cells to accumulate mutations [6,7]. It is well 
established that high levels of estrogen or prolonged exposure is associated with breast cancer 
susceptibility [8]. A reanalysis of nine prospective studies demonstrated that there was a statistically 
significant increase in breast cancer risk with increasing concentrations of endogenous sex hormones 
in postmenopausal women [9]. Thus, the proper level of endogenous estrogen is crucial for female 
health. The biosynthesis and metabolism of estrogens, the main source of endogenous estrogens,  
is a complex process. A series of enzymes, such as cytochrome P450, family 17 (CYP17),  
CYP11A, CYP19, hydroxysteroid (17-β) dehydrogenase 1 (HSD17B1), CYP1A1, CYP1A2, CYP1B1,  
catechol-O-methyltransferase (COMT), as well as many other estrogen-signaling regulatory enzymes,  
is involved in the catabolism of cholesterol into estrogens and their subsequent degradation [10].  
To exert their physiological effects, estrogens must first bind to estrogen receptors (ERs) and form 
complexes that subsequently bind to specific sequences in the promoters of estrogen-responsive  
genes [11]. Thus, all of these estrogen-related genes have been speculated to influence the synthesis or 
degradation of estrogens and are considered as candidate breast cancer susceptibility genes. 
Single-nucleotide polymorphisms (SNPs) are the most frequent type of variation in the human 
genome, and are also valuable in tests of association with common diseases and pharmacogenetic  
traits [12,13]. Many studies have evaluated the association between SNPs in estrogen-related genes, 
such as CYP17, CYP19, CYP1A1, CYP1B1, COMT, GSTP1, and ERα/β, and the risk of breast cancer, 
especially in postmenopausal women [14–21]. Polymorphisms in these genes have been reported to 
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affect the regulation, transcription, and activity of the enzymes, as well as subsequent exposure to 
endogenous estrogen and the development of breast cancer [14]. Although the effect of individual 
SNPs is usually small, multi-SNP association analysis can reveal cumulative risk effects and significantly 
relate to breast cancer [22]. Except for some reviews in which data from different reports and races were 
summarized and synthetically analyzed, most studies to date have focused on Western women [14,15]. 
Chinese populations have only been analyzed through studies with small sample sizes where few genes 
in the estrogen pathways were included. These conditions are too limited to explore and demonstrate 
special genes or SNPs of breast cancer genes in Han Chinese women comprehensively. 
In a previous study, we genotyped six SNPs in the estrogen biosynthesis gene CYP11A1, and three 
variants (rs2279357, rs2959003, and rs2959008) were identified as associated with susceptibility to 
breast cancer [23]. In the present study, we explored the role of genetic polymorphisms in additional 
estrogen-related genes in breast cancer risk to systematically identify additional risk polymorphisms. 
We selected 32 SNPs, including 14 located in estrogen biosynthesis genes (CYP17A1, HSD17B1, 
CYP19A1, and STS), seven in metabolism genes (CYP1A1, CYP1A2, CYP1B1, COMT, and GSTP1), 
six in estrogen receptors (ERα and ERβ), and five in estrogen-signaling regulatory enzymes  
(CARM1, CREBBP, NQO1, SRD5A2, and SΜLT1E1). The study was performed on Guangdong Han 
Chinese women. 
2. Results 
2.1. Subject Characteristics and Quality Control of SNPs 
The baseline characteristics of the 1076 subjects (546 controls and 530 cases) are shown in Table 1. 
The mean ages at the time of recruitment of the patients and controls significantly differed  
(48.48 ± 10.18 and 44.59 ± 11.26 years, respectively, p < 0.05); therefore, statistical analysis based on  
case-control comparisons was adjusted for age. The most common tumor histopathological type was 
invasive ductal carcinoma (IDC), accounting for 83.96% (445) compared to 4.91% (26) of other tumor 
types including invasive lobular carcinoma (ILC), mucin-producing carcinomas (Muc), and medullary 
carcinoma (Medul) and 11.13% (59) of unknown types. Only five patients (0.94%) presented with 
stage 0 (carcinoma in situ), and stages 1–4 accounted for 23.77%, 24.34%, 30.94%, and 8.87%  
of patients, respectively. The cases consisted of 270 (50.94%) ER-positive tumors, 190 (35.85%)  
ER-negative tumors, 237 (44.72%) PR-positive tumors, and 223 (42.08%) PR-negative tumors, whereas 
the remaining 70 tumors (13.21%) were untested. 
Quality control of all of the SNPs, consisting of a Hardy-Weinberg equilibrium (HWE) p > 0.05 in 
healthy controls, a genotyping rate ≥ 85%, and a minor allele frequency (MAF) > 0.01 was conducted. 
Five SNPs (rs2830, rs4680, rs707762, rs17268974, and rs1695) that deviated from HWE were omitted 
from further case-control analysis. 
2.2. Polymorphisms in Estrogen Biosynthesis Genes and Breast Cancer 
We compared the genotypic and allelic frequencies of 11 SNPs in estrogen biosynthesis genes 
based on the case-control study and observed that rs700519 in CYP19A1 was significantly associated 
with breast cancer risk. The frequency of the heterozygous genotype C/T was lower in the breast 
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cancer group than in the control group (20.9% vs. 26.2%). Women who carried the C/T genotype and 
T allele could be protected against breast cancer (OR = 0.723, 95% CI = 0.541–0.965, p = 0.028 and 
OR = 0.772, 95% CI = 0.600–0.993, p = 0.044, respectively). The results are shown in Table 2.  
No significant association was identified for the other SNPs. 
Table 1. Baseline characteristics of the study subjects. 
Variable Control (n = 546) Case (n = 530) 
Ethnicity Han Chinese women Han Chinese women 
Residence Guangdong, China Guangdong, China 
Mean age ± SD (years) * 44.59 ± 11.26 48.48 ± 10.18 
Mean age of menarche ± SD (years) 14.50 ± 1.54 14.33 ± 1.62 
Mean BMI ± SD (kg/m2) 23.33 ± 3.58 23.57 ± 3.34 
Exogenous hormone use a No 411 (75.27%) 373 (70.38%) 
Yes 107 (19.60%) 114 (21.51%) 
Unknown 28 (5.13%) 43 (8.11%) 
No. full-term pregnancies Nulliparous 25 (4.58%) 37 (6.98%) 
1 211 (38.64%) 214 (40.38%) 
2 184 (33.70%) 172 (32.45%) 
3 83 (15.20%) 66 (12.45%) 
≥4 43 (7.88%) 41 (7.74%) 
Variable in breast cancer cases 
Family history Yes 7 (1.32%) 
No 523 (98.68%) 
Tumor histopathology IDC 445 (83.96%) 
Others b 26 (4.91%) 
Unknown 59 (11.13%) 
Clinical stage (UICC) c Stage 0 (in situ) 5 (0.94%) 
Stage 1 126 (23.77%) 
Stage 2 129 (24.34%) 
Stage 3 164 (30.94%) 
Stage 4 47 (8.87%) 
Unknown 59 (11.13%) 
ER status Positive 270 (50.94%) 
Negative 190 (35.85%) 
Unknown 70 (13.21%) 
PR status Positive 237 (44.72%) 
Negative 223 (42.08%) 
Unknown 70 (13.21%) 
Abbreviation: BMI, body mass index; * p <0.05; a Include either oral contraceptives (OC) or hormone 
replacement therapy (HRT); b Mean ILC, Muc and Medul; c mean International Union Against Cancer 
(UICC) stages; invasive ductal carcinoma (IDC); invasive lobular carcinoma (ILC); mucin-producing 
carcinomas (Muc); and medullary carcinoma (Medul); ER, estrogen receptor; PR, progesterone receptor. 
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Table 2. Single single-nucleotide polymorphisms (SNPs) in estrogen biosynthesis genes 
and association with breast cancer. 
Gene SNPs 






OR (95% CI) a 
p a 
Homozygote  
OR (95% CI) a 
p a 
Rare Allele  
OR (95% CI) a 
p a 
CYP17A1 rs743572 G/A 1.287 (0.978–1.694) 0.072 1.081 (0.756–1.547) 0.669 0.531 1.074 (0.902–1.278) 0.424 
HSD17B1 rs615942 G/T 0.927 (0.694–1.237) 0.605 1.077 (0.760–1.526) 0.676 0.905 1.031 (0.866–1.227) 0.735 
CYP19A1 rs2414096 G/A 1.099 (0.833–1.451) 0.504 1.133 (0.787–1.630) 0.503 0.441 1.065 (0.896–1.267) 0.457 
CYP19A1 rs2445759 G/T 0.888 (0.359–2.193) 0.796 1.815 (0.153–21.572) 0.637 0.945 1.038 (0.471–2.288) 0.926 
CYP19A1 rs2446405 T/A 0.957 (0.712–1.286) 0.769 0.830 (0.579–1.188) 0.307 0.458 0.919 (0.774–1.091) 0.336 
CYP19A1 rs700519 C/T 0.723 (0.541–0.965) 0.028 0.845 (0.342–2.085) 0.715 0.047 0.772 (0.600–0.993) 0.044 
CYP19A1 rs10046 T/C 0.785 (0.587–1.051) 0.103 0.748 (0.527–1.064) 0.106 0.074 0.866 (0.729–1.028) 0.100 
CYP19A1 rs749292 G/A 0.994 (0.746–1.326) 0.970 1.100 (0.777–1.557) 0.593 0.627 1.045 (0.880–1.241) 0.618 
CYP19A1 rs936306 G/A 0.869 (0.672–1.125) 0.287 0.869 (0.574–1.317) 0.508 0.386 0.908 (0.755–1.092) 0.305 
CYP19A1 rs1008805 T/C 0.990 (0.766–1.278) 0.936 1.138 (0.736–1.758) 0.561 0.799 1.036 (0.860–1.248) 0.712 
CYP19A1 rs11575899 TCT/DEL 1.029 (0.797–1.328) 0.826 0.954 (0.612–1.487) 0.837 0.883 1.001 (0.830–1.207) 0.992 
Abbreviation: OR, Odds Ratio; 95% CI, 95% confidence interval; Significant values are marked in bold;  
a Adjusted by age. 
2.3. Polymorphisms in Estrogen Metabolism Genes and Breast Cancer 
Among the five SNPs in estrogen metabolism genes, the genotype distribution of CYP1A2 rs2069522 
was significantly different between cases and controls. In contrast to rs700519, the heterozygote T/C 
of rs2069522 increased the risk of breast cancer (OR = 1.500, 95% CI = 1.078–2.087, p = 0.016,  
Table 3). The other four SNPs showed no evidence of an association with breast cancer. 
Table 3. Single SNPs in estrogen metabolism genes and association with breast cancer. 
Gene SNPs 





OR (95% CI) a 
p a 
Homozygote  
OR (95% CI) a 
p a 
Rare Allele  
OR (95% CI) a 
p a 
CYP1A1 rs1531163 A/G 0.996 (0.762–1.303) 0.978 0.643 (0.283–1.459) 0.290 0.618 0.938 (0.746–1.180) 0.586 
CYP1A1 rs2606345 C/A 0.722 (0.479–1.088) 0.120 0.380 (0.034–4.241) 0.432 0.062 0.709 (0.480–1.048) 0.085 
CYP1A2 rs2069522 T/C 1.500 (1.078–2.087) 0.016 0.514 (0.127–2.081) 0.351 0.091 1.305 (0.968–1.760) 0.081 
CYP1A2 rs762551 A/C 0.876 (0.678–1.133) 0.313 0.873 (0.572–1.333) 0.529 0.362 0.914 (0.761–1.099) 0.339 
CYP1B1 rs1056836 C/G 1.073 (0.787–1.462) 0.657 0.715 (0.286–1.792) 0.475 0.964 0.997 (0.761–1.306) 0.985 
Abbreviation: OR, Odds Ratio; 95% CI, 95% confidence interval. Significant values are marked in bold.  
a Adjusted by age. 
2.4. Polymorphisms in Estrogen Receptors (ERs) and Regulatory Genes 
No significant differences were found in genotypic or allelic distributions between the case and 
control groups, indicating that the 11 SNPs in the ERs and regulatory genes were not independently 
associated with breast cancer in our study population. Detailed information is shown in Tables 4 and 5. 
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Table 4. Single SNPs in estrogen receptors and association with breast cancer. 
Gene SNPs 





OR (95% CI) a 
p a 
Homozygote  
OR (95% CI) a 
p a 
Rare Allele  
OR (95% CI) a 
p a 
ERα rs728524 A/G 1.137 (0.873–1.480) 0.340 0.628 (0.318–1.239) 0.180 0.965 0.996 (0.801–1.238) 0.972 
ERα rs2234693 T/C 1.110 (0.839–1.469) 0.465 0.986 (0.663–1.465) 0.944 0.892 1.022 (0.844–1.237) 0.823 
ERα rs9340799 A/G 0.945 (0.726–1.229) 0.671 1.222 (0.677–2.207) 0.505 0.900 1.011 (0.818–1.250) 0.918 
ERα rs3798577 T/C 0.796 (0.605–1.048) 0.104 0.927 (0.654–1.314) 0.669 0.378 0.936 (0.786–1.113) 0.454 
ERβ rs1255998 G/C 0.929 (0.712–1.212) 0.585 0.979 (0.683–1.404) 0.908 0.783 0.976 (0.818–1.164) 0.783 
ERβ rs1256049 G/A 0.951 (0.725–1.247) 0.716 1.075 (0.753–1.533) 0.692 0.925 1.022 (0.858–1.217) 0.805 
Abbreviation: OR, Odds Ratio; 95% CI, 95% confidence interval; a Adjusted by age. 
Table 5. Single SNPs in estrogen-signaling regulatory enzymes and association with breast cancer. 
Gene SNPs 





OR (95% CI) a 
p a 
Homozygote  
OR (95% CI) a 
p a 
Rare Allele  
OR (95% CI) a 
p a 
CARM1 rs12460421 G/A 1.272 (0.947–1.708) 0.110 1.024 (0.720–1.455) 0.896 0.980 1.018 (0.857–1.209) 0.841 
CREBBP rs130021 A/G 1.150 (0.877–1.507) 0.312 0.994 (0.691–1.431) 0.976 0.930 1.024 (0.859–1.220) 0.792 
NQO1 rs1469908 G/A 1.142 (0.876–1.490) 0.326 0.889 (0.435–1.819) 0.748 0.380 1.069 (0.856–1.335) 0.555 
SRD5A2 rs523349 G/C 1.068 (0.810–1.409) 0.639 1.024 (0.719–1.458) 0.897 0.742 1.019 (0.857–1.212) 0.833 
SΜLT1E1 rs3736599 G/A 0.983 (0.761–1.270) 0.896 1.105 (0.717–1.703) 0.652 0.668 1.024 (0.851–1.233) 0.801 
Abbreviation: OR, Odds Ratio; 95% CI, 95% confidence interval; a Adjusted by age. 
2.5. Cumulative Risk Analysis 
CYP11A1 encodes the key enzyme that catalyzes the initial and rate-limiting steps of steroid 
hormone synthesis. In our previous study, three SNPs, rs2279357, rs2959003, and rs2959008,  
in CYP11A1 were validated to be associated with breast cancer risk (OR = 1.558, 95% CI = 1.092–2.222, 
p = 0.014; OR = 0.668, 95% CI = 0.460–0.971, p = 0.034 and OR = 0.669, 95% CI = 0.452–0.991,  
p = 0.045) [23]. To investigate whether these significant risk polymorphisms had a cumulative effect, 
an integrated analysis including these five SNPs was performed to evaluate the cumulative risk for 
breast cancer (Table 6). We defined the genotypes C/C of rs700519, T/C of rs2069522, and T/T of 
rs2279357, rs2959003, and rs2959008 as risk genotypes to conduct statistical analysis. Consistent with 
our hypothesis, women who carried more risk genotypes had a higher susceptibility for developing 
breast cancer (ptrend = 0.030). Women with five high-risk genotypes had a statistically significant 1.286 
times higher risk of developing breast cancer than controls (OR = 2.286, 95% CI = 1.187–4.399,  
p = 0.013). 
The admixture maximum likelihood (AML) method was employed to evaluate the cumulative effect 
from multiple variants. As expected, four SNPs (rs2279357, rs2959008, rs2959003, and rs2069522) 
were significant at the 5% level (p = 0.02, 0.02, 0.03, and 0.04) after adjusting for age based on the 
trend test for association. The other SNP (rs700519) failed to reach this threshold (p = 0.08). 
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Table 6. Cumulative risk of five susceptibility SNPs for breast cancer. 
The Number of Risk Genotype Control Case OR (95% CI) a p a
1/5 220 (46.8%) 201 (41.4%) 1 - 
2/5 99 (21.1%) 110 (22.6%) 1.223 (0.873–1.714) 0.242 
3/5 81 (17.2%) 79 (16.3%) 1.118 (0.772–1.619) 0.556 
4/5 55 (11.7%) 65 (13.4%) 1.327 (0.877–2.007) 0.181 
5/5 15 (3.2%) 31 (6.4%) 2.286 (1.187–4.399) 0.013 
The five SNPs include rs700519, rs2069522, rs2279357, rs2959003, and rs2959008. Significant values are 
marked in bold; a Adjusted by age. 
The global test yielded a marginally significant association for the whole estrogen-related pathway 
(pglobal = 0.047). Dividing into four functional sub-pathways for the global test revealed strong 
associations with the estrogen biosynthesis (pglobal = 0.026) and metabolism (pglobal = 0.014) sub-pathways. 
However, the other two sub-pathways showed no association with breast cancer. 
2.6. Stratified Analysis Based on ER and Progesterone Receptor (PR) Status 
Given the significance of hormone receptors in breast cancer progression and clinical diagnosis, 
stratified analysis, based on ER and PR status and genetic polymorphisms, was performed. Finally, 
three SNPs (rs2446405, rs17268974, and rs130021) were found to be distributed differently among 
breast cancer subgroups. Genotype A/A and allele A of rs2446405 showed a stronger association  
with ER(+) tumors than ER(−) (OR = 2.072, 95% CI = 1.147–3.742, p = 0.016 and OR = 1.341,  
95% CI = 1.030–1.746, p = 0.030); however, for rs17268974, A/A was associated with ER(−) tumors 
(OR = 0.468, 95% CI = 0.243–0.900, p = 0.023). A/G carriers of rs130021 also showed a tendency 
toward PR(+) tumors (OR = 1.756, 95% CI = 1.164–2.648, p = 0.007). The complete results for the 
different inheritance models are shown in Table 7. 
Table 7. Case-case comparisons for the associations of polymorphisms by subgroups of 
ER and PR status. 
Subgroups SNPs 





OR (95% CI) 
p 
Homozygote  
OR (95% CI) 
p 
Rare Allele  
OR (95% CI) 
p 
ER status rs2446405 T/A 1.217 (0.779–1.900) 0.388 2.072 (1.147–3.742) 0.016 0.019 1.341 (1.030–1.746) 0.030 
ER status rs17268974 T/A 0.857 (0.564–1.303) 0.471 0.468 (0.243–0.900) 0.023 0.043 0.782 (0.598–1.022) 0.072 
PR status rs130021 A/G 1.756 (1.164–2.648) 0.007 1.188 (0.680–2.076) 0.545 0.205 1.193 (0.915–1.556) 0.192 
Abbreviation: ER, estrogen receptor; PR, progesterone receptor; Significant values are marked in bold. 
3. Discussion 
In the present retrospective study, two SNPs, rs700519 and rs2069522, were identified as being 
associated with breast cancer risk. The non-synonymous coding SNP rs700519 (Arg264Cys) is located 
in exon 7 of CYP19A1, which encodes aromatase, the key enzyme in estrogen biosynthesis. Aromatase 
catalyzes the rate-limiting step in the conversion of testosterone and androstenedione to estradiol and 
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estrone in a wide variety of tissues, including the ovary, placenta, brain, and adipose tissue [24].  
The up-regulation of CYP19A1 expression has been observed to contribute to breast cancer [25]. 
Individual genetic polymorphisms in this gene have also previously been reported to be associated 
with enzymatic activity (C1123T and rs28757184), with certain pathologic phenotypes including 
breast cancer (Trp39Arg), and with poor efficacy of cancer treatment (rs4646) [26–30]. Studies in 
Chinese women have identified that the common missense polymorphism rs700519 alone or combined 
with other polymorphisms could significantly modulate the risk of endometriosis [31], polycystic 
ovary syndrome [32], and survival of breast cancer [33]. In the present population, this SNP was 
significantly associated with susceptibility to breast cancer, consistent with a result based on North 
Indian women [18]. However, some studies showed no significant association [34–36]. Another key 
enzyme of the pathway is CYP1A2, which also plays a crucial role in estrogen metabolism. Genetic 
variants of CYP1A2 have been shown to contribute to the risk of lung and breast cancer by interacting 
with environmental factors and drug metabolism through regulation of enzyme activity [37–39].  
SNP rs2069522 is located at −2847 bp of CYP1A2, within a putative region that bidirectionally 
regulates the transcriptional activation of both CYP1A1 and CYP1A2 genes [40]. Despite the important 
function of rs2069522, its association with breast cancer risk has not been clearly demonstrated. 
Genetic studies have only shown that it had the potential to affect colorectal cancer risk and the 
treatment response to clozapine in schizophrenic patients among British Caucasians and Koreans, 
respectively [41,42]. However, those results were not significant after correction for multiple testing. 
Our study revealed for the first time that heterozygosity of rs2069522 significantly increased breast 
cancer risk. It is possible that this variant may influence the transcription and thus activity of CYP1A1 
protein. It is particularly worth noting that the association of rs700519 and rs2069522 was only 
observed for heterozygotes, but not for homozygotes. One possibility is that the number of rare 
homozygotes for these two SNPs is too small to show significant evidence, which is consistent with 
the HapMap database and other reports [41,43]. Furthermore, the biological function of these two 
SNPs has not been clarified fully. Thus, further analyses based on a larger set of SNPs should be 
conducted to perform fine mapping of the locus, and to explore their biological functions and 
mechanisms in more detail. 
Genetic polymorphisms in estrogen-related genes have been intensively investigated in many 
studies. However, these studies produced inconsistent results [15–18,21,31,44,45]. Several polymorphisms 
that were previously reported to contribute to breast cancer risk showed no significant association in 
our case-control analysis, including rs743572, rs1056836, rs1695, and rs2234693 [18,21,44,45].  
The inconsistency might mainly be due to racial differences in susceptibility to breast cancer [46], 
because these studies were performed on various populations and subject numbers. For instance, 
variants in CYP1B1 (rs1056836), COMT (rs4680), and ERα (rs9340799) were significantly related to 
breast cancer susceptibility among Caucasian women [20,21], but we failed to find the same 
associations in our study population. Thus, it is necessary to replicate these risk loci to validate specific 
variants for Han Chinese women. 
Polymorphisms in genes could affect the levels of transcription, translation, and activity of enzymes 
and result in wide inter-individual variability of responses to carcinogenic substances. Although the 
effect of a single polymorphism on tumorigenesis is weak, multiple loci could combine to generate  
a cumulative risk that cooperates with environmental exposure [47]. We have previously investigated 
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the polymorphisms in CYP11A1 and found that rs2279357, rs2959003, and rs2959008 were related  
to breast cancer risk [23]. Combined with two associated variants in the present study, the cumulative 
analysis of these five verified variants revealed a much higher risk than a single SNP, a finding that 
agrees remarkably well with our expectation. The pathway-based AML global test also showed  
a significant association for the whole estrogen-related pathway that was much stronger for estrogen 
biosynthesis and metabolism sub-pathways. These findings support the multigenic nature of the 
etiology of breast cancer and need for gene–gene or locus–locus interactive studies on low-penetrance 
genes to comprehensively explore the underlying mechanisms of breast cancer. 
It is necessary for all hormones to combine with their corresponding receptors to exert their 
biological functions. The expression of receptors, such as ER, PR, and human epidermal growth factor 
receptor-2 (HER2), is included in routine clinical classification and evaluation of breast cancer [48]. 
Their expression may also predict the response to targeted therapies such as tamoxifen and 
trastuzumab. Therefore, we also carried out stratified analyses based on ER and PR subtypes in the 
case group. Three SNPs (rs2446405, rs17268974, and rs130021) were confirmed to be associated with 
ER or PR status. Genetic changes in the receptors may influence their activity and therefore the risk 
and subtype of breast cancer. 
Our study had some limitations. First, menopausal status can modify a woman’s risk of developing 
breast cancer, and the incidence rate differs between premenopausal and postmenopausal women.  
In the current study, we did not evaluate the associations for postmenopausal and premenopausal 
women separately because information on menopausal status was not obtained from most of the 
participants. Second, the statistical power for all of the 1076 subjects was larger than 83% to detect a 
log-additive genotype relative risk of 1.30 (Table S1). It was considered to be well powered to detect 
strong or moderate effect sizes of disease-predisposing variants, but smaller effects might have been 
missed. In fact, the exact powers of the two significant SNPs, rs700519 and rs2069522, were 68.12% 
and 83.69%, respectively. Furthermore, some variants in estrogen-related genes, such as CYP1A1 
T3801C, CYP1A1 A2455G, and COMT Val158Met, were identified as susceptibility loci in breast 
cancer development according to recent meta-analysis reports [49–51]. However, these SNPs were not 
included in the present study because they failed in the assay design or deviated from HWE. It is worth 
noting that the significance of the results could be due to certain biases, which should be considered. 
Our study is still ongoing, and an additional large-scale assay with a more comprehensive design and 
more candidate SNPs may help to resolve these issues. It is, however, expected to improve the risk 
models for breast cancer among Han Chinese women. 
4. Experimental Section 
4.1. Ethics Statement 
The present study was reviewed and approved by the regional ethical committee of Nanfang Hospital, 
Southern Medical University, Guangzhou, Guangdong Province, China (IRB No: 2009-SCBCGS-GZ-01) 
on 12 January 2009. Written informed consent was obtained from all of the participants in the trial. 
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4.2. Study Subjects 
A total of 1076 Han Chinese women were included in the current study; 530 were cases with breast 
cancer and 546 were controls. All of the patients were recruited from Nanfang Hospital after a pathological 
diagnosis was ascertained. Clinical information was obtained from the patients’ medical records, 
including demographic characteristics, age at diagnosis, menopausal status, ER status, PR status, HER2 
status, clinical stage, degree of differentiation, size of tumor, and lymph node involvement.  
The healthy controls were derived randomly and simultaneously from the same hospital, and were 
matched by ethnicity and geographic location. All of the controls were checked by a physician for the 
absence of cancer, and family history of their first-degree relatives was self-ascertained. 
4.3. DNA Extraction 
Peripheral blood samples were collected from the participants and stored at −70 °C until DNA 
extraction. Genomic DNA was extracted from EDTA-containing blood using the EZNA blood DNA 
kit (Omega Biotek, Norcross, GA, USA) according to the manufacturer’s instructions. The DNA was 
stored at −70 °C. 
4.4. SNP Selection and Genotyping 
The rationale for SNP selection has been described in detail elsewhere [23,52]. Briefly, we selected 
candidate SNPs in estrogen-related genes from Genome-Wide Association Studies GWAS, meta-analysis 
in multiple populations, or other large-sample association studies on breast cancer [41,44,53]. 
Furthermore, SNPs that were significantly associated with other hormone-induced cancers such as 
ovarian cancer and endometrial cancer were also selected. To achieve a power of at least 50%, with an 
odds ratio of 1.3, only SNPs with MAF ≥ 10% in the Chinese population according to the HapMap 
database were included. Monomorphic SNPs among the Chinese population were discarded. Finally, 
the genotyping assay was designed using Assay Design 4.0 software (Sequenom, San Diego, CA, USA), 
and after comprehensive evaluation, a total of 32 SNPs in 16 genes were included in this study. Details 
on the locations and characteristics of these SNPs are listed in Table S2. 
For each SNP, a pair of amplification primers and an extension primer were designed using Assay 
Design 4.0 software. Genotyping was performed using the high-throughput MassARRAY iPLEX platform 
(Sequenom) through multiplex reactions. The genotyping rate of DNA samples was set to ≥85%. 
4.5. Statistical Analysis 
The statistical power of the case-control study was calculated using QUANTO software version 
1.2.4 (University of Southern California, Los Angeles, CA, USA; http://hydra.usc.edu/gxe). We conducted 
a case-control study for all of the subjects, and then the patients were stratified by ER and PR status. 
Association analysis based on unconditional logistic regression was carried out by estimating OR and 
95% CI with multiple inheritance models (codominant, dominant, recessive, overdominant, and additive) 
for each SNP. HWE was assessed using Fisher’s exact test and the χ2 test. The statistical tests  
were implemented using SPSS 13.0 software combined with the Web-based tool SNPstats 
(http://bioinfo.iconcologia.net/SNPstats). We also performed the AML-based global test of association 
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for the whole estrogen-related pathway as well as for four sub-pathways after adjusting for age using 
software provided by the authors of Tyrer et al. [54]. All of the statistical analyses were two-tailed,  
and the significance level was set at a p value of 0.05. 
5. Conclusions 
In conclusion, we have presented an integrated analysis of the relationship between common 
variants in estrogen-related genes and breast cancer risk. Our study provides molecular genetic evidence 
suggesting that the independent and combined effects of these polymorphisms potentially reflect 
exposure to estrogen and as a consequence, an increase in breast cancer susceptibility. Our data 
suggest that this association could be specific to ER status. These findings may contribute to obtaining 
a more conclusive understanding about the underlying etiology of breast cancer and provide new 
strategies for breast cancer prevention, early detection, and specific treatment. 
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